127943-95-7

Basic information

• Product Name: methyl (1R,3R)-3-(tert-butyldimethylsilyloxy)cyclohex-4-ene-1-carboxylate
• Synonyms: methyl (1R,3R)-3-(tert-butyldimethylsilyloxy)cyclohex-4-ene-1-carboxylate
• CAS NO: 127943-95-7
• Molecular Weight: 270.444
• Mol File: 127943-95-7.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: methyl (1R,3R)-3-(tert-butyldimethylsilyloxy)cyclohex-4-ene-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl (1R,3R)-3-(tert-butyldimethylsilyloxy)cyclohex-4-ene-1-carboxylate(127943-95-7)
• EPA Substance Registry System: methyl (1R,3R)-3-(tert-butyldimethylsilyloxy)cyclohex-4-ene-1-carboxylate(127943-95-7)

Safety Data

• Hazardous Substances Data: 127943-95-7(Hazardous Substances Data)

Upstream product

• 54911-89-6 (1R,5R)-methyl-5-hydroxycyclohex-3-enecarboxylate 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 31139-02-3 (1R,6S)-6-methoxycarbonyl-3-cyclohexene-1-carboxylic acid 
• 5709-98-8 (R)-cyclohex-3-enecarboxylic acid 
• 4841-84-3 dimethyl cis-1,2,3,6-tetrahydrophthalate 
• 6493-77-2 (R)-(+)-methyl 3-cyclohexene-1-carboxylate 
• 109667-78-9 N-(4-chloro-7-oxo-6-oxabicyclo[3.2.1]octan-3-yl)acetamide 
• 119719-61-8 (1R,4R,5R)-4-iodo-6-oxabicyclo[3.2.1]octane-7-one 
• 19914-76-2 (1S-cis)-6-Chlorcarbonyl-3-cyclohexen-1-carbonsaeure-methylester 
• 935-79-5 cis-1,2,3,6-tetrahydrophthalic anhydride 
• 4771-80-6 1,2,5,6-tetrahydrobenzoic acid 
• 76140-13-1 endo-4-iodo-6-oxabicyclo<3,2,1>octan-7-one 
• 4720-83-6 6-oxabicyclo[3.2.1]oct-3-en-7-one 

Downstream Products

• 1026073-45-9 methyl (1R,3R,4R,5S)-3-(tert-butyldimethylsilyloxy)-4-hydroxy-5-methylcyclohexane-1-carboxylate 
• 1339943-40-6 C₅₆H₇₆O₁₈Si 
• 1339943-42-8 C₅₀H₆₂O₁₈ 
• 1026074-30-5 (1R,2R,4R,6S)-2-tert-butyldimethylsilyloxy-4-hydroxymethyl-6-methylcyclohexyl 2,3,4-tri-O-benzyl-6-deoxy-α-L-galactopyranoside 
• 1026074-32-7 (1R,2R,4R,6S)-2-tert-butyldimethylsilyloxy-4-chloromethyl-6-methylcyclohexyl 2,3,4-tri-O-benzyl-6-deoxy-α-L-galactopyranoside 
• 1026074-33-8 (1R,2R,4R,6S)-2-tert-butyldimethylsilyloxy-4,6-dimethylcyclohexyl 2,3,4-tri-O-benzyl-6-deoxy-α-L-galactopyranoside 
• 1026074-34-9 (1R,2R,4R,6S)-2-hydroxy-4,6-dimethylcyclohexyl 2,3,4-tri-O-benzyl-6-deoxy-α-L-galactopyranoside 
• 1026073-51-7 methyl (1R,3R,4R,5S)-4-O-(2,3,4-tris-O-benzyl-6-deoxy-α-L-galactopyranosyl)-3,4-dihydroxy-5-methylcyclohexane-1-carboxylate 
• 1374760-20-9 C₁₆H₃₀O₄Si 
• 1446004-02-9 C₆₈H₇₈F₃NO₁₆ 
• 1446003-98-0 C₃₉H₆₂N₄O₁₅S 
• 1609184-34-0 C₃₂H₅₃NO₁₅ 
• 1609184-35-1 C₄₀H₆₁NO₁₉ 
• 1609184-38-4 C₅₈H₉₇N₃O₁₇ 

Relevant articles and documents

METHODS AND COMPOSITIONS FOR TREATING AND/OR PREVENTING MUCOSITIS

Methods for treating and/or preventing mucositis comprising administering to a subject in need thereof an effective amount of at least one compound chosen from E-selectin antagonists, pharmaceutically acceptable salts of E-selectin antagonists, prodrugs of E- selectin antagonists, and pharmaceutically acceptable salts of prodrugs of E-selectin antagonists, and compositions comprising at least one of such compound.

E-SELECTIN ANTAGONIST COMPOUNDS, COMPOSITIONS, AND METHODS OF USE

Methods and compositions using E-selectin antagonists are provided for the treatment and prevention of diseases and disorders treatable by inhibiting binding of E-selectin to an E-selectin ligand. Described herein are E-selectin antagonists including, for example, glycomimetic compounds, antibodies, aptamers and peptides that are useful in methods for treatment of cancers, and treatment and prevention of metastasis, inhibiting infiltration of the cancer cells into bone marrow, reducing or inhibiting adhesion of the cancer cells to endothelial cells including cells in bone marrow, and inhibiting thrombus formation. These E-selection antagonists have the general formula (Ia) below.

GLYCOMIMETIC-PEPTIDOMIMETIC INHIBITORS OF E-SELECTINS AND CXCR4 CHEMOKINE RECEPTORS

Compounds, compositions and methods are provided for treating cancer and inflammatory diseases, and for releasing cells such as stem cells (e.g., bone marrow progenitor cells) into circulating blood and enhancing retention of the cells in the blood. More specifically, glycomimetic-peptidomimetic compounds that inhibit both E-selectins and CXCR4 chemokine receptors are described.